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There is evidence that progesterone plays a role in the aetiology of invasive epithelial ovarian cancer. Therefore, genes involved in
pathways that regulate progesterone may be candidates for susceptibility to this disease. Previous studies have suggested that genetic
variants in the progesterone receptor gene (PGR) may be associated with ovarian cancer risk, although results have been inconsistent.
We have established an international consortium to pool resources and data from many ovarian cancer case–control studies in an
effort to identify variants that influence risk. In this study, three PGR single nucleotide polymorphisms (SNPs), for which previous data
have suggested they affect ovarian cancer risk, were examined. These were þ331 C/T (rs10895068), PROGINS (rs1042838), and a
30 variant (rs608995). A total of 4788 ovarian cancer cases and 7614 controls from 12 case–control studies were included in this
analysis. Unconditional logistic regression was used to model the association between each SNP and ovarian cancer risk and two-
sided P-values are reported. Overall, risk of ovarian cancer was not associated with any of the three variants studied. However, in
histopathological subtype analyses, we found a statistically significant association between risk of endometrioid ovarian cancer and the
PROGINS allele (n¼651, OR¼1.17, 95% CI¼1.01–1.36, P¼0.036). We also observed borderline evidence of an association
between risk of endometrioid ovarian cancer and the þ331C/T variant (n¼725 cases; OR¼0.80, 95% CI 0.62–1.04, P¼0.100).
These data suggest that while these three variants in the PGR are not associated with ovarian cancer overall, the PROGINS variant
may play a modest role in risk of endometrioid ovarian cancer.
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Several lines of evidence support a role for progesterone in the
aetiology of ovarian cancer (Risch, 1998). Epidemiological studies
have consistently shown a significant protective effect of parity.
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sThe protective effect increases steadily with each birth and
pregnancy is associated with high progesterone levels (Hartge
et al, 1989; Cooper et al, 1999; Titus-Ernstoff et al, 2001; Whiteman
et al, 2003; Pike et al, 2004). In the third trimester, progesterone
levels are some 10–15 times higher than in the luteal phase of the
normal menstrual cycle. Oral contraceptives are also protective
against ovarian cancer (Study, 1987; Rosenblatt et al, 1992, 1994;
Ness et al, 2000; Royar et al, 2001; Schildkraut et al, 2002) and use
of progestin-containing oral contraceptives increases average
circulating progesterone levels to 9.2ngm
 1 compared to
B3.5ngm
 1 during the normal menstrual cycle (Norman and
Litwack, 1997). The protective effect of oral contraceptives per
month of use is less than the protection from births, in line with
the concentrations of progesterone. There is also some evidence
that oral contraceptives with higher progestin content afford more
protection against ovarian cancer (Schildkraut et al, 2002).
Animal models and in vitro data also suggest that progesterone
has a significant influence on the ovary and on ovarian cancer.
Studies in macaques suggest an apoptotic effect of progestins on
the surface of the ovary (Rodriguez et al, 1998). In vitro treatment
of both benign and malignant ovarian tumour cells with progestins
results in an antiproliferative response (Zhou et al, 2002).
Progesterone binds to the progesterone receptor (PR) to initiate
signalling. Two progesterone receptor isoforms (PR-A, PR-B) are
encoded by a single gene (PGR). Except for a 164 amino-acid
sequence at the N-terminal end of PR-B that is absent from PR-A,
the PR isoforms are identical but their actions are divergent
(Kastner et al, 1990). PR-B acts as a transcription activator whereas
PR-A inhibits PR-B (and other members of the nuclear receptor
superfamily) (Vegeto et al, 1993).
The PGR has long been hypothesised as a candidate gene for
ovarian cancer susceptibility and its variation has been widely
studied. Originally, an ALU in intron 7 named PROGINS was
identified and found to be associated with increased risk of ovarian
cancer (McKenna et al, 1995; Rowe et al, 1995). Subsequent
characterisation of the coding region of the gene identified a non-
synonymous single nucleotide polymorphism (SNP) in exon 4 and
a synonymous SNP in exon 5 that were in perfect linkage
disequilibrium with the PROGINS (De Vivo et al, 2002). The
PROGINS (or variants in which it is in perfect linkage
disequilibrium) has been studied by many groups in relation to
ovarian cancer risk. The results are, however, equivocal (McKenna
et al, 1995; Manolitsas et al, 1997; Lancaster et al, 1998, 2003;
Spurdle et al, 2001; Tong et al, 2001; Agoulnik et al, 2004; Pearce
et al, 2005; Terry et al, 2005; Romano et al, 2006). Pearce et al
(2005), suggested that a variant 30 of the PGR (rs608995), in partial
linkage disequilibrium with the PROGINS, might be a better
marker of ovarian cancer risk, but this has not been confirmed by
other investigators.
In addition, a putative functional SNP, þ331C/T (sometimes
denoted as þ331G/A), in the promoter region of the PGR that may
affect the relative transcription of the PR-A and PR-B isoforms has
been found to be associated with a reduced risk of ovarian cancer
in studies from North Carolina and Australia (Berchuck et al,
2004). This association was particularly strong among clear cell/
endometrioid subtypes. However, Risch et al (2006) observed an
increased risk of ovarian cancer associated with this SNP.
The inconsistent results with the PROGINS and the þ331C/T
SNP are not surprising. Genetic association studies are plagued by
conflicting results that can be explained by heterogeneity across
study populations as well as false-positive and -negative results.
Lohmueller et al (2003) demonstrated that approximately two-
thirds of genetic associations do not hold up on meta-analysis.
Large sample sizes and pooling of data are therefore critical to
evaluate the association between a phenotype and genetic variation
with confidence.
To clarify the association between variation at the PGR locus
and ovarian cancer risk, including histological subtype associa-
tions, 12 groups from the Ovarian Cancer Association Consortium
(OCAC) have pooled their data to examine the þ331C/T variant
(rs10895068), the PROGINS allele (measured by the exon 4 non-
synonymous SNP; rs1042838) and a variant 30 of the PGR
(rs608995) in relation to ovarian cancer risk. The results are
reported here.
MATERIALS AND METHODS
Approval and consent
All study participants provided written informed consent prior to
the collection of biological samples or interview/clinical data. Each
group involved in the OCAC has Institutional Review Board/ethics
approval for this analysis and the University of Southern California
and Duke University have Institutional Review Board approval to
serve as data coordinating centres for the OCAC.
Study populations
The OCAC comprises investigators who collaborate on promising
genetic associations by combining data from their individual
ovarian cancer case–control studies. The participating groups for
this PGR study are the Australian Cancer Study, (Merritt et al,
2008) the Australian Ovarian Cancer Study (Merritt et al, 2008),
the Connecticut Ovary Study (CONN) (Risch et al, 2006), the
Family Registry for Ovarian Cancer Study (Auranen et al, 2005;
Song et al, 2006), the Hormones and Ovarian Cancer Prediction
Study, the Danish Malignant Ovarian Cancer Study (MALOVA)
(Auranen et al, 2005; Song et al, 2006), the Mayo Clinic Ovarian
Cancer Case–Control Study (Sellers et al, 2005), the North
Carolina Ovarian Cancer Study (Berchuck et al, 2004), the New
England-based Case–Control Study (NECC) (Terry et al, 2005),
the Polish Ovarian Cancer Study (POCS) (Garcı ´a-Closas et al,
2007), the UK SEARCH Ovarian Cancer Study (SEARCH)
(Auranen et al, 2005; Song et al, 2006) and the USC/Los Angeles
County Case–Control Studies of Ovarian Cancer (USC) (Pearce
et al, 2005). Details of these studies have been published previously
(Gayther et al, 2007); Table 1 shows the basic information for each
study. The cases analysed here are restricted to women diagnosed
with invasive epithelial ovarian cancer.
Genotyping and quality control
The three SNPs genotyped in this study were the þ331C/T
(rs10895068), PROGINS (measured by the exon 4 SNP rs1042838)
and rs608995 (a variant 30 of the PGR). The allele designations are
based on the forward strand as given in the University of
California at Santa Cruz genome browser.
All groups used the 50 nuclease Taqman allelic discrimination
assay (Taqman; Applied Biosystems, Foster City, CA, USA) to
genotype samples with the exception of the Australian Cancer
Study and Australian Ovarian Cancer Study, which used the iPlex
Sequenom MassArray system (Sequenom Inc., San Diego, CA,
USA), CONN that used dot blotting (Risch et al, 2006), and Mayo
Clinic Ovarian Cancer Case–Control Study that used Pyrosequen-
cing for PROGINS and rs608995.
To confirm that laboratory to laboratory quality control
was adequate, five SNPs were genotyped in the
HAPMAPPT01 panel of CEPH-Utah trios-standard plate provided
by Coriell (http://locus.umdny.edu/nigms/nigms_cgi/panel.cgi?
id¼2&query¼HAPMAP01). This 96-well plate contains 90
different DNA samples, five duplicate samples, and a negative
template control. Genotyping call rates and concordance between
studies were compared. Call rates for these five SNPs ranged from
96 to 99% and the concordance of results across the laboratories
was 499%.
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controls by the racial/ethnic group. Data from one study (CONN)
for two of the SNPs (PROGINS and rs608995) were excluded for
gross deviations (Po10
 4) from HWE. The genotyping calls for
studies with minor deviations from HWE (0.01oPo0.05) were
examined to monitor the quality of the genotyping. There were no
obvious reasons for deviation from HWE (e.g., genotyping
irregularities), and therefore the minor deviations were assumed
most likely due to chance. In addition, results were unchanged
when excluding those studies with HWE P-values between 0.01 and
0.05 (data not shown). Concordance between duplicate samples
was 100% across all studies for the three variants for all data
included in these analyses.
Results were available for 12 groups for the þ331C/T variant.
The NECC study did not genotype rs608995. Results for the
PROGINS and rs608995 were excluded for CONN due to
significant deviations from HWE. Therefore, results were available
for 11 studies for the PROGINS and 10 studies for the rs608995 30
variant.
Statistical analysis
The variables available for this analysis were study, race/ethnicity
(White, Latina, African-American), age, stage of disease (FIGO),
histology (serous, mucinous, clear cell, and endometrioid), and
time from diagnosis to blood collection (cases only).
Unconditional logistic regression was used to model the
association between each SNP and risk of ovarian cancer stratified
on study, age, and race/ethnicity. All single SNP models were log
additive. Goodness of fit P-values were calculated to evaluate
heterogeneity across the study populations. Statistical analyses
were carried out using both SAS (Version 9, Cary, NC, USA) and
Table 1 Characteristics of the 12 case–control studies used in this analysis
Cases Controls
Study
a Ascertainment N
White
(%)
Age
(mean) Ascertainment N
White
(%)
Age
(mean)
Participation
rates
ACS,
Australia
Cancer registries of New South Wales and
Victoria: cases diagnosed July 2002–June
2005.
111 91.0 59.8 Randomly selected from Commonwealth
electoral roll. Frequency matched for age
and geographical region
156 95.8 55.2
AOCS,
Australia
Diagnosed from 2002 onwards; recruited
through surgical treatment centres
throughout Australia and cancer registries
of Queensland, southern Australia and
western Australia cases diagnosed 2002–
2006.
502 95.4 59.7 Randomly selected from Commonwealth
electoral roll. Frequency matched for age
and geographical region
684 97.4 58.2 Cases: 68%
Controls: 47%
CONN,
USA
Rapid case ascertainment of consecutive
cases identified from 30 Connecticut
hospitals and through the Connecticut
Tumour Registry between 1998 and 2003
365 90.7 59.1 HCFA (CMS) plus random-digit dial
identification from study area, frequency
matched to cases on age group
533 88.6 53.1 Cases: 69%
Controls 61%
FROC,
USA
Consecutive cases diagnosed from 1997–
2002 in Greater Bay Area Cancer Registry,
San Francisco.
324 87.3 50.8 Random-digit dial identification from study
area. Frequency matched to cases for race/
ethnicity and 5-year age group
424 86.8 48.4 Cases: 75%
Controls: 91%
HOPE,
USA
Variable source including physician offices,
cancer registries and pathology databases
from counties of western Pennsylvania,
eastern Ohio and western New York.
57 95.1 57.9 Identified in same regions. Frequency
matched for age and ethnicity. All
participants undergo home interviews
152 94.7 56.1 Cases: 69%
Controls: 81%
MALOVA,
Denmark
Incident cases (35–79 years) diagnosed
1994–1999 from municipalities of
Copenhagen and Frederiksberg and
surrounding counties.
444 100.0 59.9 Random sample of general female
population (35–79 years) in study area,
selected using computerised Central
Population Register, matched to cases for
age and geographical region
1221 100 56.8 Cases: 79%
Controls: 67%
MAYO,
USA
Cases attending Mayo Clinic diagnosed
from 2000 onwards, identified in a six-state
surrounding region.
278 97.6 61.4 Identified through Mayo Clinic. Healthy
women seeking general medical
examination. Frequency matched to cases
for age, race, and state of residence
389 97.7 60.3 Cases: 84%
Controls: 65%
NCOCS,
USA
Cases from 1999 onwards, identified from
48 counties within the region by rapid-case
ascertainment.
610 83.0 56.8 Controls identified from same region.
Frequency matched to cases for age and
race
843 81.5 54.4 Cases: 70%
Controls: 63%
NECC,
USA
Cases identified through hospital tumour
boards and state cancer registries in New
Hampshire and Massachusetts from 1992
to 2003.
667 96.0 53.6 Controls identified through a combination
of random-digit dialling, town books, and
drivers’ license lists and frequency matched
to cases on age and state of residence
1011 96.6 50.5 Cases: 72%
Controls: 69%
POCS,
Poland
Cases collected from cities of Warsaw and
Lodz, 2001–2003, by rapid ascertainment
at participating hospitals
264 100.0 56.3 Identified at random through The Polish
Electronic System. Stratified by city and 5-
year age categories
625 100 56.1 Cases: 71%
Controls: 67%
SEARCH,
UK
Cases o70 years from East Anglian, West
Midlands and Trent regions of England.
Prevalent cases diagnosed 1991–1998;
incident cases diagnosed 1998 onwards.
643 99.3 55.8 Selected from the EPIC-Norfolk cohort of
25000 individuals aged 45–74, based in
the same geographical regions as the cases
852 99.7 52.7 Cases: 67%
Controls: 84%
USC, USA Rapid case ascertainment through Los
Angeles Cancer Surveillance Program from
1993 onwards
523 71.0 54.9 Neighborhood recruited controls,
frequency matched to cases for age and
ethnicity
724 75.4 52.7 Cases: 73%
Controls: 73%
aSee methods for full study name.
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sSTATA (Version 9, StataCorp, College Station TX, USA). All
statistical significance levels (P-values) quoted are two-sided. All
odds ratios are expressed per copy of the minor allele.
RESULTS
A total of 4788 invasive epithelial ovarian cancer cases and 7614
controls were available for the current analysis (Table 1). Overall,
92.0% of cases and 93.0% of controls were White and the mean
ages were 56.7 and 54.3 years respectively. Information on stage at
diagnosis was available on 73.7% of cases, the majority of which
were FIGO stage III/IV (63.0%) and 55.5% had a serous histology
(Supplementary Table 1).
Across the studies, the minor allele frequencies in White
controls ranged from 4.6 to 7.3% for þ331C/T (rs10895068), 9.2
to 19.0% for the PROGINS (rs1042838) and 20.0 to 26.6% for the 30
variant (rs608995; Supplementary Table 2). The study-specific and
summary effect estimates are shown in Figure 1 for all cases and
endometrioid subtype associations.
There was no association with the þ331C/T (rs10895068)
variant among all cases (per allele OR¼1.00; 95% CI 0.89–1.13;
P¼1.0; Table 2a). In cell type-specific subgroup analyses, a
suggestive association was observed with carrying a T allele and
risk of endometrioid invasive ovarian cancers (per allele
OR¼0.80; 95% CI 0.62–1.04; P¼0.100; Figure 1). Risk of clear
cell ovarian cancer with this variant was reduced to a similar
degree (OR¼0.83; Table 2b). No associations were observed
between serous or mucinous subtypes and this allele (Table 2b).
No overall association was observed with risk of ovarian cancer
and the PROGINS allele (rs1042838; OR¼1.04; 95% CI 0.96–1.12;
P¼0.38; Table 2a). However, risk was statistically significantly
elevated among endometrioid ovarian cancer cases (OR¼1.17,
95% CI 1.01–1.36, P¼0.036; Table 2b).
In a joint effects analysis, risk of endometrioid ovarian cancer
associated with the PROGINS was observed only among non-
carriers of the þ331 minor allele (OR¼1.22, 95% CI 1.01–1.46,
P¼0.037). Although not statistically significant, the protective
effect of the þ331 minor allele persisted among non-carriers of
the PROGINS (OR¼0.76, 95% CI 0.55–1.06, P¼0.11) and carriers
of the PROGINS (OR¼0.79, 95% CI 0.40–1.57, P¼0.50).
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Figure 1 Each panel shows the study-specific and summary odds ratios (boxes) and 95% confidence intervals (lines) for all cases and endometrioid
subtype specific results for the three PGR SNPs. The size each box is proportionate to the number of subjects genotyped. See methods for full study names.
Table 2a Summary odds ratios (per allele) and 95% CI for the three
PGR SNPs for all invasive cases among OCAC studies
Controls All cases
SNP NN OR
a (95% CI) P
+331C/T (rs10895068) 7338 4551 1.00 (0.89–1.13) 1.0
PROGINS C/A (rs1042838) 6794 4124 1.04 (0.96–1.12) 0.38
rs608995 A/T 5796 3510 1.05 (0.98–1.13) 0.17
CI¼confidence interval; OR¼odds ratio; OCAC¼Ovarian Cancer Association
Consortium; PGR¼progesterone receptor gene; SNP¼single nucleotide poly-
morphism.
aAll analyses stratified on study, race, and age.
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30 variant (rs608995) and risk of ovarian cancer when all cases were
considered (Table 2a). In subtype analysis, a borderline statisti-
cally significant association was observed between endometrioid
cases and the rs608995 variant (OR¼1.14, 95% CI 0.99–1.31,
P¼0.076), however, this effect was limited to individuals also
carrying at least one copy of the PROGINS (data not shown).
DISCUSSION
Since the publication of the first paper examining the relationship
between the PROGINS and ovarian cancer risk more than 10 years
ago, there has been substantial interest in the role of the PGR in
risk of this disease. We have evaluated three SNPs, þ331C/T
(rs10895068), PROGINS (rs1042838), and a 30 variant (rs608995),
in the PGR in a pooled ovarian cancer dataset from 12 groups
around the world and have found no overall role for this gene in
disease risk.
The pooled analysis does provide statistically significant
evidence of an association between the PROGINS and risk of
invasive endometrioid ovarian cancer. The restriction of an
association to this subtype only provides an explanation for the
equivocal nature of the published results on the PROGINS and
ovarian cancer risk, given that the proportion of endometrioid
ovarian cancer cases likely varied by published study and typically
accounts for no more than 15–20% of cases.
We also found suggestive evidence of an association between
endometrioid ovarian cancer and the þ331C/T variant
(OR¼0.80, 95% CI 0.62–1.04, P¼0.100). As suggested by
Berchuck et al (2004), combining endometrioid and clear cell
histologies in which the effect is similar, resulted in a borderline
statistically significant association (n¼1088 cases, OR¼0.81, 95%
CI 0.65–1.01, P¼0.058).
Pearce et al (2005) had previously suggested that rs608995 may
explain the PROGINS-ovarian cancer association, however, in this
larger dataset in which the effect was restricted to endometrioid
cases, this was not supported. When examining the joint effects of
the PROGINS and rs608995, the OR for endometrioid ovarian
cancer associated with the rs608995 minor allele was 0.79 (95% CI
0.59–1.07, P¼0.12) in the absence of the PROGINS allele. This
suggests that the PROGINS allele or a marker in linkage
disequilibrium with the PROGINS is responsible for the associa-
tion and not the rs608995 variant.
Both the þ331 variant and the PROGINS have been studied
with regard to their functional effect. The T allele of the þ331
favours an increase in the transcription of PR-B relative to PR-A
(De Vivo et al, 2002); PR-B acts as a classic steroid receptor
whereas PR-A acts as a repressor of both PR-B and other steroid
receptors. PR-A therefore may lessen overall progesterone
responsiveness through its repressive effect. Any variation which
increases PR-B relative to PR-A may reduce risk of ovarian cancer
by increasing exposure to the beneficial effects of progesterone. In
a small study of 107 ovarian cancer cases, decreased risk of death
was observed among cases positive for PRB (labelling index410)
relative to cases negative for PRB (P¼0.037). However, this
finding was amongst all cell types (Akahira et al, 2000). There is
also a suggestion that the PROGINS allele as defined by the V660L
exon five variant (as examined in the present study) decreases
overall response to progesterone which would be consistent with
an increased risk of disease associated with this variant (Romano
et al, 2007).
In this collaborative effort, there were 4788 ovarian cancer cases,
of which 766 (16.0%) were endometrioid tumours. With the
samples sizes available in this current OCAC study, we had 80%
power to detect odds ratios of 0.83 and 1.12 for the þ331, and
PROGINS variants, respectively for all cases using a log additive
genetic model and a two-sided a of 0.05. Among endometrioid
subtypes, we had 80% power to detect odds ratios of 0.67 and 1.25
for the þ331 and PROGINS variants, respectively using a log
additive genetic model and a two-sided a of 0.05. Although the
power in the current OCAC study is still quite limited, it
underscores the importance of collaborative efforts, as the largest
individual OCAC study had only 124 endometrioid ovarian
cancers. Thus the power of subgroups analyses is clear and will
be enhanced in the future with continued patient accrual to
existing studies and additional investigators contributing to OCAC
studies.
Alternatively, the findings of an association with the þ331C/T
and PROGINS, variants with the endometrioid histology may
simply be due to chance. By assigning priors of 0.05, 0.10, and 0.15,
the resulting false positive report probabilities (Wacholder et al,
2004) are approximately 0.78, 0.62, and 0.52 for the þ331C/T
variant and 0.61, 0.42, and 0.32 for the PROGINS, respectively.
Thus they may represent false positive findings.
Our analysis is the largest report describing the association
between ovarian cancer risk and variants in the PGR. However,
there remain several limitations to the study. For example, it is
possible that environmental modifiers, such as oral contraceptive
use, may be important in refining the PGR ovarian cancer risk
associations and such analyses are planned in the future. There are
also weaknesses of this study. Firstly, there are variable participa-
tion rates for cases between studies (Table 1). If any or all of the
variants analysed is related to survival, then the low participation
rates among cases might be expected to influence the results.
Efforts to evaluate this include the analyses of data stratified by
FIGO stage and time from diagnosis to blood collection. None of
the results differed significantly when conducting these analyses.
Second, as is the nature of collaborative projects, each study had a
different level of pathology review and random misclassification
cannot be ruled out, which would bias results towards
the null in histologic-specific analyses suggesting that our results
may be attenuated. Lastly, while we evaluated the best PGR
candidate variants suggested by the literature, it remains possible
that other, as yet unidentified variants at the locus, influence
ovarian cancer risk.
Also, we observed significant heterogeneity of effect for the
PROGINS allele and risk of ovarian cancer overall. Evaluation of
the heterogeneity by removing one study at a time revealed that the
NECC study population had a significantly different odds ratio
Table 2b Summary odds ratios (per allele) and 95% CI for the three PGR SNPs by histology among OCAC studies
Clear cell Endometrioid Mucinous cases Serous cases
SNP N OR
a (95% CI) PN OR
a (95% CI) PN OR
a (95% CI) PN OR
a (95% CI) P
+331C/T (rs10895068) 363 0.83 (0.58–1.19) 0.31 725 0.80 (0.62–1.04) 0.100 321 0.98 (0.68–1.40) 0.90 2549 1.06 (0.92–1.22) 0.44
PROGINS C/A (rs1042838) 324 0.98 (0.79–1.22) 0.88 651 1.17 (1.01–1.36) 0.036 296 1.04 (0.83–1.30) 0.76 2285 0.99 (0.90–1.08) 0.77
rs608995 A/T 252 1.00 (0.81–1.23) 0.98 528 1.14 (0.99–1.31) 0.076 262 1.09 (0.89–1.34) 0.41 1966 1.03 (0.94-1.12) 0.53
CI¼confidence interval; OR¼odds ratio; OCAC¼Ovarian Cancer Association Consortium; PGR¼progesterone receptor gene; SNP¼single nucleotide polymorphism;
N¼number of cases.
aAll analyses stratified on study, race and age.
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s(OR¼0.75, heterogeneity P¼0.011) from the other 10 OCAC
studies. We investigated possible explanations for the hetero-
geneity we observed in the NECC study, but the reason could not
be elucidated. Genotyping error is the most likely reason for
experimental bias towards the null. Therefore, we regenotyped the
PROGINS allele in the NECC case–control study. The results were
98% concordant with the original genotyping data, ruling this out
as an explanation. Also, standard epidemiological risk and
protective factors are observed with the NECC study suggesting
no coding errors in the data with respect to case–control status.
Further stratification of White race by Jewish ancestry was done
and the results were consistent across Jewish and non-Jewish
Whites (data not shown). The age distribution and participation
rates are consistent with the other OCAC studies (Table 1). This
heterogeneity may simply be due to chance.
Heterogeneity was also present with the þ331 variant and
endometrioid ovarian cancer, however no single study accounted
for this heterogeneity. The minor allele frequency of this SNP is
approximately 5% and the fluctuations in the data may simply
represent chance; further follow-up is needed.
If these are true results and variation at the PGR locus is
associated with endometrioid ovarian cancer only, then it has
implications for the identification of moderate risk genes for
ovarian cancer. In the past, ovarian cancer has frequently been
treated as a single-disease entity for genetic association studies,
mainly because studies have been too small to perform subtype
analyses that are substantially powered. However, there is a large
body of evidence that indicates different germline and somatic
genetic factors contribute to different histological subtypes of
ovarian cancer. For example, BRCA1 mutation carriers appear to
predispose to serous ovarian cancers (Pal et al, 2005); mutations in
the PTEN tumour suppressor gene are more associated with
endometrioid ovarian cancers (Obata et al, 1998); and K-ras
mutations are more common in mucinous tumours than in either
serous of endometrioid subtypes (Gemignani et al, 2003).
In conclusion, in the present analysis, we were able to exclude an
overall effect of these variants in the PGR with risk of ovarian
cancer. However, our evidence suggests histology-specific effects,
demonstrating the necessity of data pooling to examine subgroup
effects for this cancer. Although the PROGINS is unlikely to
represent appreciable susceptibility risk factor, given the restric-
tion of the association to endometrioid histology, the magnitude of
the observed odds ratio, and the modest allele frequency of this
variant, further analysis of this gene with regard to the
endometrioid subtype is warranted to provide insight into the
mechanisms underlying disease aetiology.
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